Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $15.50

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $15.50.

A number of equities research analysts have issued reports on BCRX shares. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.21 on Monday. The stock has a market capitalization of $1.91 billion, a P/E ratio of -15.10 and a beta of 1.75. The business has a 50-day moving average of $8.01 and a two-hundred day moving average of $7.84. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.50.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of BCRX. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the period. Eversept Partners LP lifted its holdings in shares of BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after acquiring an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. boosted its position in shares of BioCryst Pharmaceuticals by 65,213.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after acquiring an additional 541,270 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth about $3,983,000. Finally, Norges Bank bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $3,947,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.